France removes state funding for dementia drugs
Open accessAbstract
The first country in Europe to act on concerns over limited effectiveness
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rigorous systematic reviews by the US Task Force on Prevention found an absence of evidence of benefit and harm for screening of those not presenting with concerns.
“rigorous systematic reviews by the US Task Force on Prevention have found an absence of evidence of benefit and harm.196”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [196]
Cites
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · see citing works
Self-citationRetractedEvaluation of clinical benefits of treatments for Alzheimer's disease
Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00193-9 · Cited by 31 · see citing works
Self-citation
- Authors
- Walsh, S., King, E., & Brayne, C.
- Affiliations
- University of Cambridge (GB)
- New Cross Hospital (GB)
- Corresponding author
- Walsh, Sebastian
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-12-30
- Volume
- 367
- Pages
- l6930
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2996812514
- Cited by
- 25
- References
- 1
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 6
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10090, NF-SI-0611-10084, ACF-2019-14-008)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- dementia drugs, government funding, drug reimbursement, drug effectiveness, public funding cuts
- MeSH terms
- Cost-Benefit Analysis, Dementia, Financial Support, France, Health Policy, Humans, Nootropic Agents, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
